Haemonetics receives FDA approval for vascular closure device

Haemonetics (HAE) received FDA approval for its PerQseal Elite vascular closure system, expanding its portfolio for large-bore procedures. The device showed 0% major complications in a study, with hemostasis in under a minute. The approval follows the acquisition of Vivasure Medical. HAE plans to present clinical data at an upcoming conference.

Original reporting
Published Oct 19, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$HAE
Bullish
high confidence
Mentioned
$HAE
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

The FDA clearance provides a clear regulatory win, likely prompting short‑term price appreciation.

02

Market read

Regulatory approval is a primary catalyst that can move the stock and influence the broader device sector.

03

What to watch

Reimbursement rates and insurance coverage could limit commercial uptake.

Relevance 8/10Novelty 8/10Timing: today

Background

Haemonetics recently acquired Vivasure Medical, integrating its technology into the new PerQseal Elite system.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

FDA approved Haemonetics' PerQseal Elite vascular closure system, expanding its product portfolio.

Expected impact

likely upward pressure as investors price in the new product approval

Evidence & confidence

Regulatory clearance is a material catalyst for a medical‑device company and often triggers short‑term buying.

Market effects

strengthens the vascular‑closure segment and may boost peers with similar pipelines.

U.S. market sees added competition; European markets already have CE mark approval.

adds to overall medical‑device sector optimism worldwide.

Counterpoint

Approval may not translate to sales if adoption is slower than expected.

Key entities

  • Haemonetics Corporation

    Medical‑technology firm receiving FDA approval.

Related articles

$HAEMed

Haemonetics receives CE mark for vascular closure system

Haemonetics (NYSE:HAE) received CE Mark certification for its VASCADE MVP XL venous vascular closure system, allowing EU and other market sales. The device is designed for larger sheath procedures and uses more collagen than its predecessor. The company's portfolio includes other CE-marked vascular closure systems. According to the company, the product has driven growth in the U.S. Interventional Technologies business.

$HAEHighAI 8/10

Haemonetics Q2 Earnings Call Highlights

Haemonetics (HAE) reported 18% organic plasma revenue growth in Q2, raising its full-year apheresis revenue growth forecast. MedSurg revenue grew 6%, and margins improved slightly. The company plans increased capital expenditures for capacity expansion. HAE reaffirmed mid-single-digit MedSurg growth for fiscal 2027, with new product launches in early stages.

$HAEMedAI 8/10

Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded

Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.

$HAEHighAI 8/10

Haemonetics Corporation Q2 2027 Earnings Call Summary

Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.